1. Regeneron starting late stage trials of coronavirus drug cocktail — Bristol-Myers pays Dragonfly Therapeutics $55M to bring NK cells to neuro diseases — JNJ in $480M-plus deal with Emergent for coronavirus vaccine supply — See more on our front page news Stay updated with the latest pharma-related coronavirus news on our new page
    Dismiss Notice
  2. Please take our quick survey on how COVID-19 is impacting your job It will only take a minute or two to respond. The survey is confidential, and does not require registration. Thank you in advance for your participation. We will provide regular updates on results as responses accumulate.
    Dismiss Notice

Playing the CRO long game?

Discussion in 'Quintiles' started by anonymous, Feb 12, 2017 at 6:06 PM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    How deep does the IMS merger needs to go before QuintilesIMS divests the R&D element and drops being a CRO from their portfolio?

    R&D is looking more and more like a pure-Novella org these days, so it may have value to be sold as such or as an independent company.

  2. anonymous

    anonymous Guest

    certainly is the trend. PPD is being auctioned off maybe to LabCorp who previously bought out Covance and Parexel announced they will be spending up to 35 million in employee separations costs coming up this year.

    What's with Trump's meeting with the Pharm execs, announcing phase I and II trials to be eliminated to cut down costs??
  3. anonymous

    anonymous Guest

    Actually, they mentioned Phase II and III trials.
  4. anonymous

    anonymous Guest

    Did QuintilesIMS just sell off a big chunk of the company-the pharma sales division?